비교리스트

 카트 문의
시장보고서
상품코드
1498536

방사성의약품 시장 규모 및 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 보고서 : 용도별, 유형별, 트레이서 유형별, 최종사용자별, 지역별

Radiopharmaceuticals Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, Type, Tracer Type, End User, and Geography
발행일: | 리서치사: The Insight Partners | 페이지 정보: 영문 237 Pages | 배송안내 : 즉시배송

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

방사성의약품 시장 규모는 2023년 90억 7,000만 달러에서 2031년 265억 1,000만 달러로 급증할 것으로 예상되며, 2023-2031년 CAGR은 14.4%를 기록할 것으로 전망됩니다. 만성 질환의 유병률 증가와 표적 치료의 임상시험 증가가 방사성의약품 시장의 성장을 견인하고 있습니다.

방사성의약품은 노화 관련 질환의 진단과 치료를 효율적으로 처리할 수 있는 것으로 입증되었습니다. 향상된 표적화 능력, 더 긴 반감기, 더 적은 부작용을 가진 방사성의약품의 개발로 인해 다양한 응용 분야에서 더욱 매력적으로 변하고 있습니다. 단일 방사성의약품에 진단과 치료 기능을 결합한 세라노스틱에 대한 연구는 유망하며, 시장 성장을 더욱 촉진할 수 있습니다. 전 세계 각국 정부가 방사성의약품의 건강 상태 개선에 대한 가치를 인식함에 따라 새로운 방사성의약품의 연구개발에 대한 자금 지원 증가와 방사성의약품의 승인을 위한 규제 당국의 지원이 증가하고 있습니다. 또한, 시장은 변화하는 헬스케어 수요에 대응하기 위해 발전하고 있으며, 첨단 진단 기술을 이용한 방사성의약품 시설의 진화는 향후 몇 년 동안 새로운 방사성의약품 시장 동향을 가져올 것으로 예상됩니다.

만성질환의 증가가 방사성의약품 시장을 견인

폐질환, 암, 뇌졸중, 알츠하이머병, 심혈관질환(CVD), 만성신장질환, 각종 신경질환 등 만성질환은 전 세계적으로 빠르게 증가하고 있습니다. 세계보건기구(WHO)에 따르면 2020년에는 전 세계적으로 암으로 인한 사망자가 1,000만 명에 달할 것으로 보고되고 있습니다. 마찬가지로 미국 암 협회의 추산에 따르면 2020년 미국에서 180만 6590명의 암 환자가 새로 진단될 것으로 예상됩니다. 국가 암 등록 프로그램 보고서 2020에 따르면, 인도에서는 남성의 경우 679,421명의 암 환자가 보고되었으며, 2025년까지 -763,575명으로 증가할 것으로 예상됩니다. 반면 여성은 2020년에 712,758명의 암 환자가 기록되었으며, 2025년까지 806,218명에 이를 것으로 예측됩니다. 미국암협회 보고서에 따르면 2023년에는 43,720명(여성 31,180명, 남성 12,540명)의 갑상선암 환자가 새로 발생할 것으로 예상되며, CVD는 높은 사망률을 초래하는 만성질환 중 가장 널리 퍼져 있는 질환 중 하나입니다. 미국 질병예방통제센터(CDC)는 심장병이 미국 내 사망원인 1위라고 밝혔습니다. 이 자료에 따르면 2020년 미국에서는 약 697,000명, 즉 5명 중 1명이 심장병으로 사망할 것으로 예상하고 있습니다. 파킨슨 재단에 따르면 파킨슨 증상은 보통 60세 이상에서 나타납니다. 캐나다 심리학회에 따르면 캐나다 인구의 약 2%가 강박장애를 앓고 있으며, WHO에 따르면 신경질환은 전 세계 질병부담의 6.3%를 차지하며 세계 주요 사망원인 중 하나입니다. 선진국과 중저소득 국가에서는 각각 13.2%와 16.8%가 신경질환으로 인한 사망으로 보고되고 있습니다. 방사성의약품은 신경질환, 신경퇴행성 질환, 근골격계 질환의 진단에 있어 높은 효능이 입증되었습니다. 방사성의약품은 그 이중적 기능성으로 인해 다른 의약품과 차별화됩니다. 방사성의약품은 질병의 가시성을 높일 뿐만 아니라 중요한 기능적 정보를 제공합니다. 다양한 방법 중 방사성 동위원소를 이용한 세포 표지법은 세포를 추적하고 생체 내 분포를 조사하기 위한 가장 유망한 기술 중 하나입니다. 이처럼 만성질환의 급증은 방사성의약품 시장의 성장을 견인하고 있습니다.

시장 동향

발전하는 방사성의약품 시설

핵의학은 많은 변화를 겪고 있는 분야입니다. 방사성의약품의 급속한 발전과 함께 PET, 방사선치료제 등 첨단 진단기술이 널리 사용되고 있습니다. 저소득 국가에서는 국제원자력기구(IAEA)의 노력으로 이 기술이 아직 확립되지 않았지만, 미국과 같은 기술 선진국에서는 특히 테라노스틱스의 출현으로 표준 치료로 발전하고 있습니다.

아프리카의 일부 국가는 IAEA의 기술 협력 프로그램과 조정된 연구 프로젝트의 지원을 받아 방사성의약품 제조를 위해 방사성의약품 시설을 확장하고 현대화하기 위해 노력하고 있습니다. 예를 들어, 북아프리카의 튀니지는 IAEA의 지원을 받아 PET를 사용하기 시작했습니다. 동시에 알제리에서는 의료용 사이클로트론을 설치하여 가동하기 시작했습니다. 이 장비를 통해 알제리는 방사성의약품을 생산할 수 있게 되었고, 림프종, 폐암, 대장암 등 많은 종류의 암에 대한 PET를 통한 정기적인 영상 진단을 할 수 있게 되었습니다.

방사성의약품 동향에 관한 국제 심포지엄에서는 방사성의약품 화학 및 핵의학의 밝은 미래를 소개합니다. 동위원소 제조, 방사성 화학의 발전, 새로운 방사성의약품의 인체 시험에의 적용은 흥미로운 결과를 가져다 줄 것입니다. 특히, 이미징을 이용하여 표적 치료를 유도하는 세라노스틱 전략과 성장하는 연구 분야는 전 세계 핵의학계가 새로운 방사선 치료제의 개발을 통해 개인 맞춤형 의료의 가능성을 실현하는 데 도움을 주고 있습니다. 세라노스틱은 진단과 치료를 하나의 접근법으로 통합하는 것입니다. 방사성 추적자는 특정 표적을 식별(진단)한 후 표적 치료를 수행합니다. 이 접근 방식을 통해 의사는 치료 반응을 실시간으로 평가하여 환자의 치료 계획을 개별화할 수 있습니다. 세라노스틱은 전립선암, 신경내분비종양 등 특정 암 치료에 특히 유망합니다. 새로운 방사성 추적자 및 이미징 약물은 분자 이미징을 보다 특이적이고 민감하게 만들어 질병을 보다 조기에 정확하게 감지할 수 있게 해줍니다. 또한 PET-CT 및 PET-MRI와 같은 하이브리드 이미징은 두 가지 이상의 영상 양식을 결합하여 보완적인 정보를 제공하고 진단 정확도를 향상시킵니다. 이러한 접근 방식은 기능적 정보와 해부학적 정보를 결합하여 질병 과정에 대한 종합적인 개요를 제공합니다. 따라서 이러한 신흥 시장 개척과 접근 방식은 향후 시장 성장을 주도할 것으로 예상됩니다.

"세계 방사성의약품 시장"은 용도, 트레이서 유형, 최종사용자, 지역별로 구분됩니다.

용도 기반 인사이트

방사성의약품 시장은 종양학, 순환기학, 신경학, 호흡기학, 비뇨기과 및 기타 분야로 분류됩니다. 암 분야는 2023년 가장 큰 시장 점유율을 차지할 것으로 예상되며, 예측 기간 동안 14.8%의 가장 높은 CAGR을 기록할 것으로 예상됩니다. 암은 사망률이 높은 주요 건강 문제 중 하나이며, 세계보건기구(WHO)의 발표에 따르면 2020년 전 세계적으로 1,010만 명의 암 환자가 새로 진단되고 1,000만 명이 암으로 사망한 것으로 추산됩니다. 암 환자의 진단과 치료를 위해서는 정확한 관리 결정과 최적의 결과를 보장하기 위해 영상 진단에 대한 접근이 필요합니다. 암 치료에는 핵의학 요법이 사용되며, 가장 일반적인 방사성 추적자는 F-18 플루오르데옥시글루코스(FDG)입니다. FDG는 포도당과 유사하며, 암세포는 신진대사가 활발해 포도당 흡수율이 높기 때문에 FDG를 흡수하는 속도가 빠릅니다. 이는 PET 검사로 확인할 수 있기 때문에 의료 전문가가 질병을 발견할 수 있습니다. Fluorodeoxyglucose로 표시된 Fluor-i8은 악성 종양과 양성 종양을 구별하고 질병의 정도를 결정하는 데 효과적이며, 2018년 1월 FDA가 루테튬 Lu 177 도타테이트(Lutathera)를 승인함에 따라 신경내분비종양(NET) 환자들은 PRRT에 대한 접근성이 확대되었습니다.

최종사용자 기반 인사이트

최종사용자별로 시장은 병원 및 클리닉, 진단 센터, 학술 및 연구 기관, 기타로 구분됩니다. 병원 및 클리닉 부문은 2023년 방사성의약품 시장 점유율을 독차지했습니다. 진단센터 부문은 2023-2031년 14.8%의 가장 높은 CAGR을 기록할 것으로 예상됩니다. 병원과 클리닉은 심장 동맥류, 종양, 신경 동맥류 및 기타 치료 절차에 기술적으로 진보된 치료법을 활용하고 있습니다. 심혈관계 및 신경계 동맥류 치료에 대한 수요 증가는 병원 및 클리닉 부문의 시장 성장을 촉진하는 주요 요인 중 하나입니다. 대부분의 수술은 지속적인 환자 관리 및 모니터링을 위해 병원에서 이루어지고 있습니다.

미국 식품의약국, 유럽연합, 세계보건기구(WHO), 국제원자력기구(IAEA), 미국 질병통제예방센터(Centers For Disease Control And Prevention), 미국 국립암연구소(National Cancer Institute), 미국 의약품청(National Medical Products Administration), 경제협력개발기구(Organization for Economic Co-Operation And Development), 캐나다 원자력안전위원회(Canadian Nuclear Safety Commission) 등은 방사성의약품 시장조사 보고서를 작성할 때 참고한 관련 정보원 중 일부입니다.

목차

제1장 소개

제2장 주요 요약

  • 주요 인사이트

제3장 조사 방법

  • 조사 범위
  • 2차 조사
  • 1차 조사

제4장 방사성의약품 시장 상황

  • PEST 분석
  • 가격 분석
    • 지역별 가격 분석, 미국(1회 투여 근처)

제5장 방사성의약품 시장 - 주요 시장 역학

  • 방사성의약품 시장 - 주요 시장 역학
  • 시장 성장 촉진요인
    • 만성질환 유병률 상승
    • 표적 치료의 임상시험 수 증가
  • 시장 성장 억제요인
    • 방사성의약품의 짧은 유통기한
  • 시장 기회
    • 신흥 국가의 높은 성장 가능성
  • 향후 동향
    • 진화하는 방사성의약품 시설
  • 성장 촉진요인과 억제요인의 영향

제6장 방사성의약품 시장 : 세계 시장 분석

  • 방사성의약품 시장 매출, 2023-2031년

제7장 방사성의약품 시장 분석 : 용도별

  • 종양학
  • 순환기
  • 신경학
  • 호흡기
  • 비뇨기과
  • 기타

제8장 방사성의약품 시장 분석 : 유형별

  • 진단
  • 치료

제9장 방사성의약품 시장 분석 : 트레이서 유형별

  • Tc-99m
  • F-18
  • Ga-68
  • TL-201
  • I-131
  • Fe-59
  • Lu-171
  • RB-82 및 N-13
  • Cr-51 및 P-32
  • Sc-46
  • Sg-269 및 Hs-269
  • 기타

제10장 방사성의약품 시장 분석 : 최종사용자별

  • 병원 및 진료소
  • 진단 센터
  • 학술·연구기관
  • 기타

제11장 방사성의약품 시장 : 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 호주
    • 한국
    • 기타 APAC
  • 중동 및 아프리카
    • 사우디아라비아
    • 남아프리카공화국
    • 아랍에미리트
    • 기타 중동 및 아프리카
  • 중남미
    • 브라질
    • 아르헨티나
    • 기타 중남미

제12장 방사성의약품 시장 : 업계 상황

  • 방사성의약품 시장의 성장 전략
  • 무기적 성장 전략
  • 유기적 성장 전략

제13장 기업 개요

  • Cardinal Health Inc
  • Curium
  • General Electric Co
  • Medi-Radiopharma
  • Rotem Industries Ltd
  • ABX advanced biochemical compounds GmbH
  • Invicro LLC
  • Newcastle University
  • Novartis AG
  • Blue Earth Diagnostics Limited
  • IBA Radiopharma Solutions

제14장 부록

ksm 24.06.26

The radiopharmaceuticals market size is projected to surge from US$ 9.07 billion in 2023 to US$ 26.51 billion by 2031; the market is estimated to record a CAGR of 14.4% during 2023-2031. The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy propel the radiopharmaceuticals market growth.

Radiopharmaceuticals have proven to handle the diagnosis and treatment of age-related diseases efficiently. The development of radiopharmaceuticals with improved targeting capabilities, longer half-lives, and fewer side effects makes them more attractive for various applications. Research into theranostics that combine diagnostic and therapeutic functions in a single radiopharmaceutical is promising and could further drive the market growth. As governments across the world recognize the value of radiopharmaceuticals in improving health outcomes, an increase in the funding for research and development of new radiopharmaceuticals and supportive regulatory pathways for their approval has been observed. Further, the market is progressing toward meeting the demands of a changing healthcare landscape, and the evolving radiopharmacy facilities using advanced diagnostic techniques are expected to bring new radiopharmaceuticals market trends in the coming years.

Rising Prevalence of Chronic Diseases Drives the Radiopharmaceuticals Market

Chronic diseases such as lung diseases, cancer, stroke, Alzheimer's, cardiovascular diseases (CVDs), chronic kidney disease, and various neurological disorders are increasing swiftly across the world. As per the World Health Organization (WHO), in 2020, ~10 million deaths were reported due to cancer globally. Likewise, as per the estimations of the American Cancer Society, in 2020, ~1,806,590 new cases of cancer were diagnosed in the US. As per the National Cancer Registry Program Report 2020, in India, 679,421 cancer cases were reported in males, and the number is anticipated to increase to ~763,575 by 2025; whereas in females, 712,758 cancer cases were recorded in 2020, and the number is predicted to reach 806,218 by 2025. According to the American Cancer Society's report, in 2023, ~43,720 new cases of thyroid cancer (31,180 in women and 12,540 in men) were recorded. CVDs are among the most prevalent types of chronic diseases that result in a high mortality rate. The Centers for Disease Control and Prevention states that heart disease is the leading cause of death in the US. According to the same source, in 2020, ~697,000 deaths, i.e., 1 in 5 deaths, were caused by heart disease in the US. According to the Parkinson's Foundation, Parkinson's symptoms are usually observed in individuals aged 60 years and above. The Canadian Psychological Association states that about 2% of the population in Canada suffers from obsessive-compulsive disorder. As per the WHO, neurological diseases contribute to 6.3% of the global disease burden and are also among the leading causes of death worldwide. 13.2% and 16.8% of deaths are reported due to neurological diseases in developed and low- and middle-income countries, respectively. Radiopharmaceuticals have been demonstrated to have high efficiency in diagnosing neurological and neurodegenerative disorders and musculoskeletal conditions. Radiopharmaceuticals are set apart due to their dual functionality. They not only enhance the visualization of diseases but also provide crucial functional information. Among the various methods available, radioisotope cell labeling is one of the most promising techniques to track cells to investigate their biodistribution. Thus, the surging incidence of chronic diseases is driving the radiopharmaceuticals market growth.

Market Trend

Evolving Radiopharmacy Facilities

Nuclear medicine is a field that is undergoing many changes. As radiopharmaceuticals evolve rapidly, more advanced diagnostic techniques such as PET and radiotherapeutics are becoming more widely used. In low-income countries, the technology is still being established, owing to the efforts by the International Atomic Energy Agency (IAEA), while in some of the technologically advanced countries such as the US, it is evolving into standard care, particularly with the advent of theranostics.

Several African countries are working toward expanding and modernizing their radiopharmaceutical facilities to produce radiopharmaceutical medicines with the help of IAEA's Technical Cooperation Program and coordinated research projects. For instance, with IAEA's support, Tunisia, a country in North Africa, started using PET. At the same time, in Algeria, a medical cyclotron was installed and commissioned. The machine enables the country to produce its radiopharmaceuticals and enables routine PET imaging for many types of cancer, such as lymphoma and lung and colon cancer.

The International Symposium on Trends in Radiopharmaceuticals showcases the bright future of radiopharmaceutical chemistry and nuclear medicine. Advances in isotope production, radiochemistry, and the implementation of novel radiopharmaceuticals in human studies lead to exciting results. In particular, theranostic strategies, which use imaging to guide targeted therapy, and the growing areas of research are helping the global nuclear medicine community realize the potential of personalized medicine through the development of new radiotherapeutics. Theranostics merges diagnostics and therapy in a single approach. Radioactive tracers identify specific targets (diagnosis) and then perform targeted therapies. This approach lets physicians personalize treatment plans for patients by assessing their response to therapy in real time. Theranostics are particularly promising for the treatment of certain forms of cancer, such as prostate cancer and neuroendocrine tumors. With new radiotracers and imaging agents, molecular imaging is becoming more specific and sensitive, enabling earlier and more accurate disease detection. In addition, hybrid imaging, such as PET-CT and PET-MRI, combines two or more imaging modalities to provide complementary information and improve diagnostic accuracy. These approaches combine functional and anatomical information, enabling a comprehensive overview of disease processes. Therefore, such developments and approaches are expected to drive the market growth in the future.

The "Global Radiopharmaceuticals Market" is segmented on the basis of application, tracer type, end user, and geography.

Application-Based Insights

Based on application, the radiopharmaceuticals market analysis is carried out by considering the following segments: oncology, cardiology, neurology, pulmonary, urology, and others. The oncology segment held the largest market share in 2023 and is anticipated to register the highest CAGR of 14.8% during the forecast period. Cancer is one of the major health problems with a high mortality rate. As per the WHO, in 2020, an estimated 10.1 million new cancer cases were diagnosed, and 10 million people died from cancer worldwide. The diagnosis and treatment of patients with cancer require access to imaging to ensure accurate management decisions and optimal outcomes. Nuclear medicine therapy is used to treat cancer, and the most common radiotracer is F-18 fluorodeoxyglucose (FDG). FDG is similar to glucose, and cancer cells are more metabolically active; therefore, they absorb glucose at a higher rate. This can be seen on PET scans and thereby allows the healthcare professional to detect the disease. Fluorine-i8 labeled as flurodeoxyglucose is effective in differentiating malignant from benign tumors and in determining the extent of the disease. People with neuroendocrine tumors (NETs) have wider access to PRRT following the FDA approval of lutetium Lu 177 dotatate (Lutathera) in January 2018.

End User-Based Insights

By end user, the market is segmented into hospitals and clinics, diagnostic centers, academic and research institutes, and others. The hospitals and clinics segment dominated the radiopharmaceuticals market share in 2023. The diagnostic centers segment is anticipated to register the highest CAGR of 14.8% during 2023-2031. Hospitals and clinics utilize technologically advanced treatment for cardiac aneurysms, oncology tumors, neurology aneurysms, and other treatment procedures. The growing need for cardiovascular and neurology aneurysm treatments has become one of the major factors driving the market growth for the hospitals and clinics segment. Most of the surgeries are being performed in hospitals, owing to the continuous patient care and monitoring.

US Food and Drug Administration, European Union, World Health Organization, International Atomic Energy Agency, Centers For Disease Control And Prevention, National Cancer Institute, National Medical Products Administration, Organization For Economic Co-Operation And Development, and Canadian Nuclear Safety Commission are some of the relevant sources referred while preparing the radiopharmaceuticals market research report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Radiopharmaceuticals Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Pricing Analysis
    • 4.3.1 Regional Pricing Analysis, US$ (Per Dose)

5. Radiopharmaceuticals Market - Key Market Dynamics

  • 5.1 Radiopharmaceuticals Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Diseases
    • 5.2.2 Growing Number of Clinical Trials in Targeted Therapy
  • 5.3 Market Restraints
    • 5.3.1 Short Shelf-Life of Radiopharmaceuticals
  • 5.4 Market Opportunities
    • 5.4.1 High Growth Potential in Developing Countries
  • 5.5 Future Trends
    • 5.5.1 Evolving Radiopharmacy Facilities
  • 5.6 Impact of Drivers and Restraints:

6. Radiopharmaceuticals Market - Global Market Analysis

  • 6.1 Radiopharmaceuticals Market Revenue (US$ Million), 2023-2031

7. Radiopharmaceuticals Market Analysis - by Application

  • 7.1 Overview
  • 7.2 Oncology
    • 7.2.1 Overview
    • 7.2.2 Oncology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Cardiology
    • 7.3.1 Overview
    • 7.3.2 Cardiology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Neurology
    • 7.4.1 Overview
    • 7.4.2 Neurology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Pulmonary
    • 7.5.1 Overview
    • 7.5.2 Pulmonary: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Urology
    • 7.6.1 Overview
    • 7.6.2 Urology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

8. Radiopharmaceuticals Market Analysis - by Type

  • 8.1 Overview
  • 8.2 Diagnostic
    • 8.2.1 Overview
    • 8.2.2 Diagnostic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Diagnostic
  • 8.3 Therapeutic
    • 8.3.1 Overview
    • 8.3.2 Therapeutic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.3.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Therapeutic

9. Radiopharmaceuticals Market Analysis - by Tracer Type

  • 9.1 Overview
  • 9.2 Tc-99m
    • 9.2.1 Overview
    • 9.2.2 Tc-99m: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Tc-99m
  • 9.3 F-18
    • 9.3.1 Overview
    • 9.3.2 F-18: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Ga-68
    • 9.4.1 Overview
    • 9.4.2 Ga-68: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 TL-201
    • 9.5.1 Overview
    • 9.5.2 TL-201: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 I-131
    • 9.6.1 Overview
    • 9.6.2 I-131: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Fe-59
    • 9.7.1 Overview
    • 9.7.2 Fe-59: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Lu-171
    • 9.8.1 Overview
    • 9.8.2 Lu-171: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.9 RB-82 and N-13
    • 9.9.1 Overview
    • 9.9.2 RB-82 and N-13: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.10 Cr-51 and P-32
    • 9.10.1 Overview
    • 9.10.2 Cr-51 and P-32: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.11 Sc-46
    • 9.11.1 Overview
    • 9.11.2 Sc-46: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.12 Sg-269 and Hs-269
    • 9.12.1 Overview
    • 9.12.2 Sg-269 and Hs-269: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.13 Others
    • 9.13.1 Overview
    • 9.13.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

10. Radiopharmaceuticals Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
    • 10.2.1 Overview
    • 10.2.2 Hospitals and Clinics: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Academic and Research Institutes
    • 10.4.1 Overview
    • 10.4.2 Academic and Research Institutes: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

11. Radiopharmaceuticals Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Radiopharmaceuticals Market Overview
    • 11.2.2 North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.2.4 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.2.4.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.2.4.2 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.2.5 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.2.5.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.2.6 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.2.7 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.1.1 United States: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.1.2 United States: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.1.2.1 United States: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.1.2.2 United States: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.1.3 United States: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.1.3.1 United States: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.1.4 United States: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.2 Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.2.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.2.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.2.3 Canada: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.2.3.1 Canada: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.2.4 Canada: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.3 Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.3.2 Mexico: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.3.2.1 Mexico: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.3.2.2 Mexico: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.3.3 Mexico: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.3.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.3.4 Mexico: Radiopharmaceuticals Market Breakdown, by End User
  • 11.3 Europe
    • 11.3.1 Europe Radiopharmaceuticals Market Overview
    • 11.3.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.3.4 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.3.4.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.3.4.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.3.5 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.3.5.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.3.6 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.3.7 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.1.1 Germany: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.1.2 Germany: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.1.2.1 Germany: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.1.2.2 Germany: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.1.3 Germany: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.1.3.1 Germany: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.1.4 Germany: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.2 United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.2.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.2.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.2.3 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.2.3.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.2.4 United Kingdom: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.3 France: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 France: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.3.2 France: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.3.2.1 France: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.3.2.2 France: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.3.3 France: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.3.3.1 France: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.3.4 France: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.4 Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 Italy: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.4.2 Italy: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.4.2.1 Italy: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.4.2.2 Italy: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.4.3 Italy: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.4.3.1 Italy: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.4.4 Italy: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.5 Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 Spain: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.5.2 Spain: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.5.2.1 Spain: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.5.2.2 Spain: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.5.3 Spain: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.5.3.1 Spain: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.5.4 Spain: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.6 Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.6.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.6.2.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.6.2.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.6.3 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.6.3.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.6.4 Rest of Europe: Radiopharmaceuticals Market Breakdown, by End User
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Radiopharmaceuticals Market Overview
    • 11.4.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.4.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.4.2.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.4.2.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.4.2.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.4.2.3.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.4.2.4 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.4.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 China: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 China: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.1.2 China: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.1.2.1 China: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.1.2.2 China: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.1.3 China: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.1.3.1 China: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.1.4 China: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.2 Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.2.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.2.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.2.3 Japan: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.2.3.1 Japan: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.2.4 Japan: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.3 India: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.3.2 India: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.3.2.1 India: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.3.2.2 India: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.3.3 India: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.3.4 India: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.4 Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Australia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.4.2 Australia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.4.2.1 Australia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.4.2.2 Australia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.4.3 Australia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.4.3.1 Australia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.4.4 Australia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.5 South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.5.1 South Korea: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.5.2 South Korea: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.5.2.1 South Korea: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.5.2.2 South Korea: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.5.3 South Korea: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.5.3.1 South Korea: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.5.4 South Korea: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.6 Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.6.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.6.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.6.2.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.6.2.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.6.3 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.6.3.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.6.4 Rest of APAC: Radiopharmaceuticals Market Breakdown, by End User
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Radiopharmaceuticals Market Overview
    • 11.5.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.5.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.5.2.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.5.2.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.5.2.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.5.2.3.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.5.2.4 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.5.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.1.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.1.2.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.1.2.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.1.3 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.1.3.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.1.4 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.2 South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.2.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.2.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.2.3 South Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.2.3.1 South Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.2.4 South Africa: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.3 United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.3.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.3.2.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.3.2.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.3.3 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.3.4 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.4 Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.4.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.4.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.4.2.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.4.2.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.4.3 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.4.3.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.4.4 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by End User
  • 11.6 South and Central America
    • 11.6.1 South and Central America Radiopharmaceuticals Market Overview
    • 11.6.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.6.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.6.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.6.2.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.6.2.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.6.2.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.6.2.3.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.6.2.4 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.6.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.6.3.1 Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.1.1 Brazil: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.1.2 Brazil: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.1.2.1 Brazil: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.1.2.2 Brazil: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.1.3 Brazil: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.1.3.1 Brazil: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.1.4 Brazil: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.2 Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.2.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.2.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.2.3 Argentina: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.2.3.1 Argentina: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.2.4 Argentina: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.3 Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.3.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.3.2.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.3.2.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.3.3 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.3.4 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by End User

12. Radiopharmaceuticals Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Radiopharmaceuticals Market
  • 12.3 Inorganic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Organic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Cardinal Health Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Curium
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 General Electric Co
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Medi-Radiopharma
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Rotem Industries Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 ABX advanced biochemical compounds GmbH
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Invicro LLC
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Newcastle University
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Novartis AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Blue Earth Diagnostics Limited
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 IBA Radiopharma Solutions
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제